Old Web
English
Sign In
Acemap
>
authorDetail
>
M. Fernandez-Navarro
M. Fernandez-Navarro
Medicine
Pathology
Clinical trial
Breast cancer
Bevacizumab
3
Papers
4
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
EP1.04-05 Outcomes of Immunotherapy in Elderly Patients. Retrospective Study of Clinical Characteristics in a Single-Center and a 4-Year Experience
2019
Journal of Thoracic Oncology
A. L. Ortega Granados
D. Fernández Garay
N. Cárdenas Quesada
J.F. Marin-Pozo
L. Díaz Beltrán
C. De la Torre Cabrera
M. Ruiz Sanjuan
M. Fernandez-Navarro
M.A. Moreno Jiménez
P Sanchez Rovira
Show All
Source
Cite
Save
Citations (0)
P1.07-036 LC-HRMS Metabolomics Profiling in Advanced NSCLC Treated with Anti PD-1 Agents. Metabolic Features at Diagnosis and at Response Evaluation
2017
Journal of Thoracic Oncology
A. L. Ortega Granados
F.J. García Verdejo
N. Cárdenas Quesada
M. Ruiz Sanjuan
C. Díaz Navarro
C. De la Torre Cabrera
M. Fernandez-Navarro
G Pérez Chica
F. Vicente Pérez
Ma Moreno Jiménez
N. Luque Caro
B. Márquez Lobo
A. Jaén Morago
R. Dueñas García
E. Martinez-Ortega
P. Sanchez Rovira
J. Pérez del Palacio
Show All
Source
Cite
Save
Citations (0)
Predictive response factors (PRF) in an open, nonrandomized, phase II study of a combination of bevacizumab (BZ) and sequential chemotherapy as preoperative treatment in patients with operable HER2-negative breast cancer (BC).
2010
Journal of Clinical Oncology
P. Sanchez Rovira
J de la Haba
M. Fernandez-Navarro
Ma Segui
Antonio Llombart-Cussac
Antonio Antón
Emilio Alba
E. Aranda
Show All
Source
Cite
Save
Citations (4)
1